The New England Journal has the first two clinical trials of the H1N1 Influenza vaccine. The data are summarized in an editorial: NEJM — Pandemic Influenza Vaccine Policy — Considering the Early Evidence.
The standard vaccine seems to generate an adequate immune response in healthy adults after a single dose. It depends on the results of other trials, but maybe we’ll only need one dose of this vaccine. They were talking about two doses for everyone, which would pose a problem since supplies will be limited.
One dose should also be OK for older kids and pregnant women. No data yet on younger children and immunosuppressed persons (older and/or with chronic diseases).
No major adverse effects seen but the studies were not large enough to detect rare side effects.
